AngioDynamics’ (ANGO) Buy Rating Reiterated at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of AngioDynamics (NASDAQ:ANGO) in a research note published on Wednesday morning,Benzinga reports. HC Wainwright currently has a $16.00 target price on the medical instruments supplier’s stock. HC Wainwright also issued estimates for AngioDynamics’ Q1 2026 earnings at ($0.14) EPS, Q2 2026 earnings at ($0.10) EPS, Q3 2026 earnings at ($0.08) EPS, Q4 2026 earnings at $0.02 EPS and FY2026 earnings at ($0.30) EPS.

Separately, Canaccord Genuity Group set a $17.00 target price on shares of AngioDynamics and gave the stock a “buy” rating in a report on Wednesday.

AngioDynamics Stock Down 0.6%

Shares of ANGO stock opened at $8.69 on Wednesday. The firm has a 50 day moving average price of $9.86 and a two-hundred day moving average price of $10.07. The company has a market capitalization of $352.90 million, a PE ratio of -10.47 and a beta of 0.60. AngioDynamics has a 12-month low of $5.83 and a 12-month high of $13.50.

AngioDynamics (NASDAQ:ANGO) last issued its quarterly earnings data on Tuesday, July 15th. The medical instruments supplier reported ($0.03) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.12) by $0.09. The firm had revenue of $80.16 million during the quarter, compared to the consensus estimate of $74.26 million. AngioDynamics had a negative net margin of 11.62% and a negative return on equity of 3.20%. The business’s revenue for the quarter was up 13.0% compared to the same quarter last year. During the same period last year, the business posted ($0.06) earnings per share. As a group, research analysts expect that AngioDynamics will post -0.37 EPS for the current year.

Institutional Inflows and Outflows

Hedge funds have recently made changes to their positions in the business. Quinn Opportunity Partners LLC bought a new position in shares of AngioDynamics during the fourth quarter worth approximately $92,000. ProShare Advisors LLC bought a new position in AngioDynamics in the fourth quarter valued at approximately $100,000. Graham Capital Management L.P. bought a new position in AngioDynamics in the fourth quarter valued at approximately $106,000. OneDigital Investment Advisors LLC increased its stake in AngioDynamics by 14.0% in the fourth quarter. OneDigital Investment Advisors LLC now owns 12,137 shares of the medical instruments supplier’s stock valued at $111,000 after acquiring an additional 1,490 shares during the last quarter. Finally, Cerity Partners LLC increased its stake in AngioDynamics by 22.0% in the first quarter. Cerity Partners LLC now owns 12,929 shares of the medical instruments supplier’s stock valued at $121,000 after acquiring an additional 2,333 shares during the last quarter. 89.43% of the stock is owned by institutional investors.

AngioDynamics Company Profile

AngioDynamics, Inc, a medical technology company, engages in the design, manufacture, and sale of medical, surgical, and diagnostic devices for the use in treating peripheral vascular disease, and oncology and surgical settings in the United States and internationally. The company offers Auryon Atherectomy system that is designed to deliver an optimized wavelength, pulse width, and amplitude to remove lesions while preserving vessel wall endothelium.